Trial · NCT01620216
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Activity | Group I (Dasatinib) | 1 | Participants | ||
| Clinical Activity | Group II (Sutinib Malate) | 0 | Participants | ||
| Clinical Activity | Group III (Sorafenib Tosylate) | 4 | Participants | ||
| Overall Objective Response Rates (Complete and Partial) | Group I (Dasatinib) | Partial response | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group II (Sutinib Malate) | Partial response | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group III (Sorafenib Tosylate) | Partial response | 1 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group I (Dasatinib) | Progressive disease | 2 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group II (Sutinib Malate) | Progressive disease | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group III (Sorafenib Tosylate) | Progressive disease | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group I (Dasatinib) | Stable disease | 2 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group II (Sutinib Malate) | Stable disease | 2 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group III (Sorafenib Tosylate) | Stable disease | 4 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group I (Dasatinib) | Not assessable | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group II (Sutinib Malate) | Not assessable | 0 | Participants | |
| Overall Objective Response Rates (Complete and Partial) | Group III (Sorafenib Tosylate) | Not assessable | 1 | Participants | |
| Progression-free Survival | Group I (Dasatinib) | 1 | Participants | ||
| Progression-free Survival | Group II (Sutinib Malate) | 1 | Participants | ||
| Progression-free Survival | Group III (Sorafenib Tosylate) | 0 | Participants | ||
| Progression-free Survival | Group IV (Ponatinib Hydrochloride) | 0 | Participants | ||
| Progression-free Survival | Group V (Pacritinib) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01620216/results